Skip to content

Author

H. Tumani

We have 4 of 95 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Neurofilaments support the differentiation of amyotrophic lateral sclerosis from degenerative cervical myelopathy.

The differential diagnosis between degenerative cervical myelopathy (DCM) and early amyotrophic lateral sclerosis (ALS) is often clinically challenging; laboratory tests that support this distinction could be highly valuable. This study examined the concentrations of neurofilament light chain (NfL) and the phosphorylat...

Julia Goebell, F. Bachhuber, Jutta Karmann et al. · 0 citations
Open access Aug 2026

Biomarker-based assessment of cerebral small vessel disease progression after ischemic stroke – a prospective cohort study (MA-BIO)

Cerebral small vessel disease (CSVD) is a leading cause of ischemic stroke and vascular cognitive impairment, yet currently lacks clinically established biomarkers for monitoring disease activity. While clinical routine magnetic resonance imaging (MRI) can provide quantitative measures of structural brain changes, it d...

L. Hasanova, P. Klassen, A. Nosanova et al. · 0 citations
Open access Aug 2026

Frailty in Adults With Down Syndrome: Cognitive, Functional and Biomarker Associations.

BACKGROUND Down syndrome (DS) entails widespread age-related functional decline affecting multiple organ systems, including genetically determined early-onset Alzheimer disease (DSAD), resulting in an increased vulnerability to frailty early in life. We investigated the relationship between frailty, cognition and intel...

Georg S. Nuebling, Lena Marth, K. Sandkühler et al. · 0 citations
Open access Aug 2026

Kappa Free Light Chain for Diagnosis and Neurofilament Light Chain for Prognosis in Autoimmune Encephalitis

Intrathecal KFLC synthesis represents a highly sensitive CSF marker that supports early suspicion of autoimmune encephalitis and prompts antibody testing and NfL provides robust biochemical information on baseline disease severity and longitudinal changes that may aid prognostic assessment across AE subtypes.

F. Konen, E. Bucak, F. Bachhuber et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.